Brokerages Expect Insmed Incorporated (NASDAQ:INSM) to Announce -$0.66 EPS

Equities analysts expect Insmed Incorporated (NASDAQ:INSM) to announce ($0.66) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Insmed’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.62). Insmed posted earnings per share of ($1.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 42.1%. The firm is expected to issue its next earnings results on Tuesday, October 29th.

On average, analysts expect that Insmed will report full year earnings of ($2.99) per share for the current financial year, with EPS estimates ranging from ($3.09) to ($2.92). For the next year, analysts expect that the firm will report earnings of ($2.46) per share, with EPS estimates ranging from ($2.79) to ($2.03). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Insmed.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $30.00 million for the quarter, compared to analyst estimates of $26.30 million.



A number of equities analysts have issued reports on the company. Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a research report on Thursday. Credit Suisse Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Insmed in a research report on Tuesday, September 10th. ValuEngine raised Insmed from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. BidaskClub raised Insmed from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 12th. Finally, Goldman Sachs Group assumed coverage on Insmed in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $36.63.

Shares of INSM traded up $0.24 during trading on Thursday, reaching $19.63. The company’s stock had a trading volume of 69,853 shares, compared to its average volume of 904,618. The company has a fifty day moving average of $17.22 and a two-hundred day moving average of $24.75. Insmed has a twelve month low of $11.31 and a twelve month high of $33.13. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -4.71 and a beta of 2.98. The company has a quick ratio of 7.31, a current ratio of 7.54 and a debt-to-equity ratio of 1.01.

In other news, CEO William Lewis sold 400,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $26.00, for a total value of $10,400,000.00. Following the completion of the sale, the chief executive officer now directly owns 480,672 shares in the company, valued at approximately $12,497,472. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.95% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC increased its holdings in shares of Insmed by 0.6% in the 1st quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock valued at $338,107,000 after acquiring an additional 67,250 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Insmed by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,979,937 shares of the biopharmaceutical company’s stock valued at $204,287,000 after acquiring an additional 896,047 shares during the last quarter. Vivo Capital LLC grew its stake in Insmed by 49.4% during the 2nd quarter. Vivo Capital LLC now owns 1,748,174 shares of the biopharmaceutical company’s stock worth $44,753,000 after buying an additional 577,884 shares during the last quarter. Eagle Asset Management Inc. bought a new position in Insmed during the 2nd quarter worth $38,439,000. Finally, Carillon Tower Advisers Inc. bought a new position in Insmed during the 2nd quarter worth $26,785,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.